Time from baseline to intervention (e.g., increase in dose of DA-agonist; addition of another DA-agonist, levodopa, or other PD therapy; or discontinuation due to lack of efficacy); or time from baseline to the last follow up, if the event did not occur

Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data.

Actual values and mean change from Baseline in percentage and total hours of awake time per day in the OFF state and ON state, UPDRS I-IV, II and III Scores during ON and OFF states, Global Clinical Impression-Improvement (CGI-I), safety

325

All

30 Years and older (Adult, Senior)

NCT00456794

6002-US-006

March 2002

October 2003

October 2003

April 5, 2007

July 14, 2016

Contact Kyowa Pharmaceutical, Inc.Princeton, New Jersey, United States